{"organizations": [], "uuid": "e7abd11c1600cb7bedde5e7311a8cad1e7f97040", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alder-says-eptinezumab-met-primary/brief-alder-says-eptinezumab-met-primary-endpoint-in-pivotal-phase-3-promise-2-clinical-trial-idUSASB0C02C", "country": "US", "domain_rank": 408, "title": "BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T14:39:00.000+02:00", "replies_count": 0, "uuid": "e7abd11c1600cb7bedde5e7311a8cad1e7f97040"}, "author": "", "url": "https://www.reuters.com/article/brief-alder-says-eptinezumab-met-primary/brief-alder-says-eptinezumab-met-primary-endpoint-in-pivotal-phase-3-promise-2-clinical-trial-idUSASB0C02C", "ord_in_thread": 0, "title": "BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "eptinezumab met primary endpoint in pivotal phase", "sentiment": "negative"}, {"name": "bla", "sentiment": "none"}, {"name": "alder biopharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "alder biopharmaceuticals inc", "sentiment": "none"}, {"name": "eptinezumab", "sentiment": "none"}, {"name": "clinical trial reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 40 PM / Updated 14 minutes ago BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial Reuters Staff 1 Min Read \nJan 8 (Reuters) - Alder Biopharmaceuticals Inc: \n* ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION \n* ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL \n* ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​ \n* ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE \n* ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​ \n* ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018  ", "external_links": [], "published": "2018-01-08T14:39:00.000+02:00", "crawled": "2018-01-08T15:01:01.100+02:00", "highlightTitle": ""}